Athari BioSciences, Inc.

Startup

Athari BioSciences, founded in July 2021, is transforming infectious disease monitoring through our groundbreaking composite alpha-pseudovirus high-throughput assay. This innovative platform delivers precise, strain-specific quantitative measurements of neutralizing antibodies, enabling comprehensive surveillance against critical pathogens including SARS-CoV-2, influenza A/B (H5N1), and Respiratory Syncytial Virus (RSV).

 

Athari Bio’s technology stands apart with three key advantages: industry-leading six-hour turnaround time, fully automated processing capabilities, and integrated cytotoxicity analysis. This versatility enables rapid adaptation to emerging infectious diseases, facilitating real-time outbreak monitoring and precise hotspot identification across varied populations.

 

CLIA-validated for SARS-CoV-2, our assay demonstrates exceptional performance with 98% sensitivity and specificity. This remarkable accuracy makes it the ideal platform for Immunobridging studies evaluating next-generation vaccines and therapeutics. Our ongoing research explores its potential as a crucial biomarker for post-acute infection syndromes, including Long COVID, offering hope for millions affected worldwide.

 

Partner with Athari BioSciences to harness the power of next-generation immune surveillance technology. Our scalable platform can support your research, clinical trials, and population health initiatives. Contact us today to discover how our innovative solutions can accelerate your development timeline and strengthen global health security. Together, we can build a more resilient future for communities worldwide.